Cancer Treatment Reviews
Volume 30, Issue 5 , Pages 451-459 , August 2004

Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches

References 

  1. Seruca R, Castedo S, Correia C, et al.  Cytogenetic findings in eleven gastric carcinomas. Cancer Genet. Cytogenet. 1993;68:42–48
  2. El Rifai W, Powell SM. Molecular biology of gastric cancer. Seminars in Radiation Oncology. 2002;12:128–140
  3. Wu CW, Chen GD, Fann CS, et al.  Clinical implications of chromosomal abnormalities in gastric adenocarcinomas. Genes Chromosomes Cancer. 2002;35:219–231
  4. El Rifai W, Frierson HJ, Moskaluk C, et al.  Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology. 2001;121:592–598
  5. Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR. Genetic alterations in Barrett's esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am. J. Pathol. 1998;153:287–294
  6. Kuniyasu H, Yasui W, Yokozaki H, et al.  Frequent loss of heterozygosity of the long arm of chromosome 7 is closely associated with progression of human gastric carcinomas. Int. J. Cancer. 1994;59:597–600
  7. Chung YJ, Choi JR, Park SW, Kim KM, Rhyu MG. Evidence for two modes of allelic loss:multifocal analysis on both early and advanced gastric carcinomas. Virchows Arch. 2001;438:31–38
  8. Rhyu MG, Park WS, Meltzer SJ. Microsatellite Instability occurs frequently in human gastric carcinoma. Oncogene. 1994;9:29–32
  9. Fleisher AS, Esteller M, Wang S, et al.  Hypermethylation of the hMLH1 gene promoter in human gastric cancers with Microsatellite Instability. Cancer Research. 1999;59:1090–1095
  10. Wu MS, Lee CW, Shun CT, et al.  Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. Genes Chromosomes Cancer. 2000;27:403–411
  11. Furlan D, Casati B, Cerutti R, et al.  Genetic progression in sporadic endometrial and gastrointestinal cancers with high microsatellite instability. J. Pathol. 2002;197:603–609
  12. Tahara E. Histone Acetylation and Retinoic Acid Receptor beta DNA Methylation as Novel Targets for Gastric Cancer Therapy. Drug News Perspect. 2002;15:581–585
  13. Worm J, Guldberg P. DNA methylation:an epigenetic pathway to cancer and a promising target for anticancer therapy. J. Oral. Pathol. Med. 2002;31:443–449
  14. Brown R, Strathdee G. Epigenetic cancer therapies:DNA methyltransferase inhibitors. Expert Opin. Investig. Drugs. 2002;11:747–754
  15. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene. 2002;21:5496–5503
  16. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann. Oncol. 2002;13:1699–1716
  17. Strathdee G. Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin. Cancer Biol. 2002;12:373–379
  18. Machado JC, Oliveira C, Carvalho R, et al.  E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene. 2001;20:1525–1528
  19. Humar B, Graziano F, Cascinu S, et al.  Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene. 2002;21:8192–8195
  20. Tanaka M, Kitajima Y, Sato S, Miyazaki K. Combined evaluation of mucin antigen and E-cadherin expression may help select patients with gastric cancer suitable for minimally invasive therapy. Br. J. Surg. 2003;90:95–101
  21. Zhou YN, Xu CP, Han B, et al.  Expression of E-cadherin and β-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J. Gastroenterol. 2002;8:987–993
  22. Mingchao , Devereux TR, Stockton P, et al.  Loss of E-cadherin expression in gastric intestinal metaplasia and later stage p53 altered expression in gastric carcinogenesis. Exp. Toxicol. Pathol. 2001;53:237–246
  23. Ishii HH, Gobe GC, Pan W, Yoneyama J, Ebihara Y. Apoptosis and cell proliferation in the development of gastric carcinomas:associations with c-myc and p53 protein expression. J. Gastroenterol. Hepatol. 2002;17:966–972
  24. Okuyama T, Maehara Y, Kabashima A, Takahashi I, Kakeji Y, Sugimachi K. Combined evaluation of expressions of p53 and p21 proteins as prognostic factors for patients with gastric carcinoma. Oncology. 2002;63:353–361
  25. Feng CW, Wang LD, Jiao LH, Liu B, Zheng S, Xie XJ. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions:correlation with clinical features. BMC Cancer. 2002;2(1):8
  26. Sakai H, Okamoto E. Clinical importance of serum anti-p53 antibodies as tumor markers. Rinsho Byori. 2002;50:970–975
  27. Pan W, Ishii H, Ebihara Y, Gobe G. Prognostic use of growth characteristics of early gastric cancer and expression patterns of apoptotic, cell proliferation, and cell adhesion proteins. J. Surg. Oncol. 2003;82:104–110
  28. Testino G, Gada D, De Iaco F, Cornaggia M. p53 and Ki-67 expression in epithelial gastric dysplasia and in gastric cancer. Panminerva Med. 2002;44:369–371
  29. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanism of action and clinical strategies. Nature reviews cancer. 2003;3:330–338
  30. Boku N, Chin K, Hosokawa K, et al.  Biological markers as predictor of response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin. Cancer Res. 1998;4:1469–1474
  31. Lenz HJ, Leichman CG, Danenberg KD, et al.  Thymidilate synthase mRNA level in adenocarcinoma of the stomach:a predictor for primary tumour response and overall survival. J. Clin. Oncol. 1996;14:176–182
  32. Alexander HR, Grem JL, Hamilton JM, et al.  thymidylate synthase protein expression. Cancer J. Sci. Am. 1995;1:49
  33. Yeh KH, Shun CT, Chen CL, et al.  High expression of thymidilate synthase is associated with drug resistance of gastric adenocarcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer. 1998;82:1626–1631
  34. Suda Y, Kuwashima Y, Tanaka Y, et al.  Immunohistochemical detection of thymidilate synthase in gastric cancer:a prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy by 5-fluoropyrimidines. Anticancer Res. 1999;19:805–810
  35. van Rees BP, Saukkonen K, Ristimaki A, et al.  Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J. Pathol. 2002;196:171–179
  36. Joo YE, Oh WT, Rew JS, Park CS, Choi SK, Kim SJ. Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion. 2002;66:222–229
  37. Xue YW, Zhang QF, Zhu ZB, Wang Q, Fu SB. Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma. World J. Gastroenterol. 2003;9:250–253
  38. Hirose M, Miwa H, Kobayashi O, et al.  Inhibition of proliferation of gastric epithelial cells by a cyclooxygenase 2 inhibitor, JTE522, is also mediated by a PGE2-independent pathway. Aliment Pharmacol. Ther. 2002;16(Suppl 2):83–89
  39. Jiang XH, Lam SK, Lin MC, et al.  Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta (1)-dependent pathway. Oncogene. 2002;21:6113–6122
  40. Yonemura Y, Ohoyama S, Kimura H, et al.  The expression of proliferative-associated nuclear antigen p105 in gastric carcinoma. Cancer. 1991;67:2523–2528
  41. Ross JS, McKenna BJ. The HER-2/neu Oncogene in tumors of the gastrointestinal tract. Cancer Investigation. 2001;19:554–568
  42. Ougolkov A, Yamashita K, Bilim V, Takahashi Y, Mai M, Minamoto T. Abnormal expression of E-cadherin, beta-catenin, and c-erb B-2 in advanced gastric cancer:its association with liver metastasis. Int J Colorectal Dis 2003;18:160–6 [Epub 2002 Aug 10]
  43. Tsigris C, Karayiannakis AJ, Syrigos KN, et al.  Clinical significance of soluble c-erb B-2 levels in the serum and urine of patients with gastric cancer. Anticancer Res. 2002;22:3061–3065
  44. Funato T, Kozawa K, Fujimaki S, Miura T, Kaku M. Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene. Chemotherapy. 2001;47:297–303
  45. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res. 2002;62:5813–5817
  46. Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 2002;62:3151–3158
  47. Zhang H, Wu J, Meng L, Shou CC. Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. World J. Gastroenterol. 2002;8:994–998
  48. Shinkaruk S, Bayle M, Lain G, Deleris G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr. Med. Chem. Anti-Canc. Agents. 2003;3:95–117
  49. Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Expert Opin. Biol. Ther. 2003;3:263–276
  50. Song ZJ, Gong P, Wu YE. Relationship between the expression of iNOS,VEGF,tumor angiogenesis and gastric cancer. World J. Gastroenterol. 2002;8:591–595
  51. Kopp R, Ruge M, Rothbauer E, et al.  Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res. 2002;22:1161–1167
  52. Garcia I, Vizoso F, Martin A, et al.  Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann. Surg. Oncol. 2003;10:234–241
  53. Doi T, Koizumi W, Siena S, et al. Efficacy, tolerability and pharmacokinetics of gefinitib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc ASCO 2003 [abstr 103]
  54. Rojo F, Tabernero J, Van Cutsem E, et al. Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefinitib (ZD1839). Proc ASCO 2003 [abstr 764]
  55. Wang ZH, Wang CY, Liu XJ, Wang LG, Li M, Chen CZ. Relationship between recurrence and metastasis of gastric cancer and expression of EGFR, IL-6R, PCNA, and DI. Ai Zheng. 2002;21:785–789
  56. Li L, Zhang S, Lin H, Lin JY. Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas. Ai Zheng. 2002;21:305–310
  57. Bramhall SR, Hallissey MT, Whiting J, et al.  Marimastat as maintenance therapy for patients with advanced gastric cancer:a randomised trial. Br. J. Cancer. 2002;86:1864–1870
  58. Ribic CM, Sargent DJ, Moore MJ, et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003;349:247–257

PII: S0305-7372(04)00027-1

doi: 10.1016/j.ctrv.2004.01.001

Cancer Treatment Reviews
Volume 30, Issue 5 , Pages 451-459 , August 2004

Article Tools